{
  "id": 15595099,
  "title": "BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026",
  "url": "https://urgent.news/2026/10/19/beone-medicines-highlights-rapidly-accelerating-solid-tumor-franchise",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-19T10:11:40.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/beone-medicines-highlights-rapidly-accelerating-solid-tumor-franchise-at-esmo-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipeline Multiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer SAN CARLOS,…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}